title: BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.
abstract: OBJECTIVE
  The aim of this study was to explore BRCA mutation frequency and to evaluate its impact on prognosis of advanced-stage ovarian cancer patients treated with debulking surgery and platinum-based chemotherapy.
  
  
  METHODS
  Patients with advanced-stage epithelial ovarian cancer were enrolled in a prospective, single-center study from September 2008 to December 2011. All cases were screened for BRCA1 and BRCA2 gene mutations. Progression-free survival (PFS) was assessed between BRCA1/2 mutation carriers and BRCA1/2 wild-type patients.
  
  
  RESULTS
  One hundred seven patients were enrolled and screened for BRCA1 and BRCA2 mutations; 51.4% patients were positive for BRCA1/2 gene mutation, 63.6% of which carried a single Baltic mutation, and 98.2% of them had serous histology. Older age (hazard ratio [HR], 1.032; 95% confidence interval [CI], 1.010-1.055; P = 0.0047), nonoptimal cytoreduction (HR, 3.170; 95% CI, 1.986-5.060; P < 0.0001), and BRCA1/2 wild type (HR, 1.625 [1.003-2.632]; P = 0.0486) were significantly associated with shorter PFS in multivariate Cox regression analysis. Only the nonoptimal cytoreduction was a statistically significant risk factor for shorter overall survival (HR, 2.684; 95% CI, 1.264-5.701; P= 0.0102).
  
  
  CONCLUSIONS
  Advanced ovarian cancer patients harboring BRCA1/2 mutation treated with debulking surgery and platinum-based adjuvant chemotherapy have a longer PFS.
authors.affiliation: *Clinics of Internal, Family Medicine, and Oncology, Faculty of Medicine, Vilnius University; †Department of Gynecology, Centre of Obstetrics and Gynecology, and ‡Hematology, Oncology, and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos; §Vilnius University Institute of Oncology; ∥Department of Molecular and Regenerative Medicine, Hematology, Oncology; and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos; and ¶State Research Institute, Innovative Medicine Center, Vilnius, Lithuania.
authors.forename: Vilius
authors.initials: V
authors.lastname: Rudaitis
authors.forename: Tadas
authors.initials: T
authors.lastname: Zvirblis
authors.forename: Daiva
authors.initials: D
authors.lastname: Kanopiene
authors.forename: Dovile
authors.initials: D
authors.lastname: Janulynaite
authors.forename: Laimonas
authors.initials: L
authors.lastname: Griskevicius
authors.forename: Ramunas
authors.initials: R
authors.lastname: Janavicius
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D011379:Prognosis; D012307:Risk Factors; D055815:Young Adult
chemical_list: D002945:Cisplatin